Le Lézard
Classified in: Health
Subject: RCL

Updated Food Recall Warning (Allergen) - Thai Best brand Thailand Black Tiger Shrimp Size 16-20 recalled due to undeclared sulphites


Product photos are available: https://inspection.canada.ca/eng/1624495844593/1624495849945

OTTAWA, ON, June 23, 2021 /CNW/ - The food recall warning issued on June 3, 2021 has been updated to include additional product information. This additional information was identified during the Canadian Food Inspection Agency's (CFIA) food safety investigation.

Searay Foods Inc. is recalling Thai Best brand Thailand Black Tiger Shrimp Size 16-20 from the marketplace because they contain sulphites which are not declared on the label. Consumers with a sensitivity to sulphites should not consume, and distributors, retailers and food service establishments such as restaurants, should not sell or use the recalled product described below.

The following product has been sold as indicated in the table below.

Recalled product

Brand

Product

Size

UPC

Codes

Additional Information 

Thai Best

Thailand Black Tiger Shrimp (Raw Headless Shell-on)

Size 16-20

4lb x 6 packs

 

4 lb

Outer Box:

10827510097484

 

Inner Box:

 8 27510 00483 6

 

Production Date: 2021/01/05

Best Before: 2023/01/05

Lot Number: 2012042THL

Sold to HRI / Retail in British Columbia

 

Thai Best or None

 

 

Thailand Black Tiger Shrimp (Raw Headless Shell-on)

Size 16-20

(may be unlabeled)

Variable (sold clerk-served)

None

All units sold up to and including June 17, 2021

Sold at Hanahreum Mart Inc, 1780-4151 Hazelbridge Way, Richmond BC

 

Sold at New Pacific Supermarket Ltd, 1056-1163 Pinetree Way,

Coquitlam, BC

 

Sold at New Empire Supermarket Ltd. , 111-4600 No. 3 Road,

Richmond, BC

 

Sold at SY Farm Market, 2438 East Hastings, Vancouver, BC

 

Sold at Wah Shang Seafood, 232-2800 East 1st Avenue, Vancouver, BC

 

Sold at Wah Shang Supermarket, 8108 Park Road, Richmond, BC

 

What you should do

Check to see if you have the recalled product in your home or establishment. Recalled products should be thrown out or returned to the location where they were purchased.

If you have a sensitivity to sulphites, do not consume the recalled product as it may cause a serious or life-threatening reaction.

Background

This recall was triggered by CFIA test results. The CFIA is conducting a food safety investigation, which may lead to the recall of other products. If other high-risk products are recalled, the CFIA will notify the public through updated Food Recall Warnings.

The CFIA is verifying that industry is removing the recalled product from the marketplace.

Reactions

There have been no reported reactions associated with the consumption of this product.

SOURCE Canadian Food Inspection Agency (CFIA)


These press releases may also interest you

at 10:31
Recently, GenScript Biotech Corporation (HK.1548), a world leader in technologies and services for life science R&D and manufacture, released its 2023 Environmental, Social, and Governance (ESG) report. This report showcases the company's dedicated...

at 10:30
Vaccines Market in terms of revenue was estimated to be worth $78.0 billion in 2024 and is poised to reach $94.9 billion by 2029, growing at a CAGR of 4.0% from 2024 to 2029 according to a new report by MarketsandMarketstm. Similarly, the vaccines...

at 10:25
Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through the development of potentially best-in-class IL-2 therapeutics, today announced that updated Phase 1/2 data for AU-007 will be presented at the American Society...

at 10:20
A monument park and website honoring medical frontline and essential workers worldwide who risked their lives during the COVID-19 pandemic will break ground this summer in Chicago, Illinois. The COVID-19 Monument of Honor, Remembrance, and Resilience...

at 10:20
Precigen, Inc. , a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced clinical data from the pivotal Phase 2 study of PRGN-2012 AdenoVerse immunotherapy...

at 10:20
The two poster presentations will report -first combination data from the Phase 1/2a study with BI-1808 in combination with MSD's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), as well as an update on monotherapy armcombination data from the...



News published on and distributed by: